Table 1.
Baseline characteristics
| Characteristics | |
|---|---|
| Number of patients | 31 |
| Number of lesions | 48 |
| Median age (range), years | 69 (45–90) |
| Gender | |
| Male | 19 |
| Female | 12 |
| Primary site | |
| Oropharynx | 9 |
| Hypopharynx/Larynx | 7 |
| Oral cavity | 6 |
| Salivary glands | 6 |
| Nose | 1 |
| CUP | 2 |
| Histology | |
| Squamous cell cancer | 26 |
| P16-negative | 16 |
| P16-positive | 7 |
| P16 unknown | 3 |
| Nonsquamous cell cancer | 5 |
| OMD | |
| Synchronous | 8 |
| Metachronous | 23 (include 1 oligorecurrent) |
| Treatment of primary | |
| Primary chemoradiotherapy | 11 |
| Surgery + adjuvant radiotherapy | 11 |
| Surgery + adjuvant chemoradiotherapy | 4 |
| Surgery | 3 |
| Radiotherapy | 2 |
| Treated metastatic lesions (total) | 48 |
| Pulmonary | 37 |
| Lymph node | 5 |
| Spine | 2 |
| Adrenal gland | 1 |
| Renal | 1 |
| Brain | 1 |
| Regional recurrence | 1 |
| Median dose as EQD2 α/β 10 (range), Gy | 88 (31.2–93.8) |
| Median number of fractions (range) | 3 (1–12) |
| Prior chemotherapy for the metastatic disease | |
| Yes (induced OMD) | 3 |
| No (de novo) | 28 |
| Systemic therapy during metastatic stage | |
| Chemotherapeutics (include cetuximab) | 12 |
| Immunotherapy (anti-PD-1) | 6 |
| None | 16 |
OMD oligometastatic disease, Gy Gray, CUP cancer of unknown primary, EQD2 median equivalent dose in 2 Gy per fraction